Coherus BioSciences Inc at H C Wainwright Healthcare Conference Transcript
We're ready to go. So welcome, everybody. I'm Doug Tsao. I cover biopharmaceuticals at H.C.W. We're pleased to have a sort of fireside chat or analyst discussion with Coherus, who is represented by Denny Lanfear, CEO of the company. Owning that, I think, for coming up on 4 years of knowing Denny, and it's been really impressive and gratifying to see the progress that he's made. I think when I first met him, they had just completed some of the clinical work on UDENYCA, which is their pegfilgrastim biosimilar, which is now launched and trending incredibly well on the market. And I think I've been noting to people, it's been, by far, the most successful biosimilar launch to date in the U.S. market.
Questions & Answers
So with that, Denny, maybe provide a little bit of an update in terms of UDENYCA's commercialization. Where you are today? Where
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
